N Govindarajan, the managing director of Aurobindo Pharma, has submitted his resignation, the pharmaceutical firm said on October 1.
Govindarajan has decided to step down due to "personal reasons", Aurobindo Pharma said in a regulatory filing. The board of directors has accepted the resignation. It will come into effect from December 31.
Meanwhile, Aurobindo's board has taken note of the appointment of S Damodharan as chief operating officer (COO) for the API vertical. Also, P Yugandhar has been appointed as the chief executive officer (CEO) of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the company focused on generic injectables and oncology business.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.